iCell® Cardiac Progenitor Cells

Cardiac progenitor cells derived from human iPS cells, frozen

More Views

iCell® Cardiac Progenitor Cells

Cardiac progenitor cells derived from human iPS cells, frozen

5 x 106 cells
Catalog #70919
1,200 USD

.

Overview

Cardiac progenitor cells (CPCs) are able to proliferate and have the capacity to differentiate into mature cardiomyocytes. Thus, these cells are attractive targets in drug development applications for regenerative medicine programs focused on developing myocardial infarction and congestive heart failure treatments. They are also ideal for identifying and helping to avoid drug-mediated cardiac developmental toxicity problems across multiple programs, an application for which scientists require consistent and dependable access to human CPCs.

Derived from human induced pluripotent stem (iPS) cells, CDI’s iCell® Cardiac Progenitor Cells provide a robust, reproducible, and relevant source of cells to advance drug development and cardiac regenerative medicine programs. Benefits include:

- KDR+/PDGFR-α+/c-Kit- human CPC marker profile
- bFGF-mediated proliferation
- WNT inhibitor-mediated differentiation into cTNT+ cardiomyocytes
- High-throughput target and phenotypic-based screen compatibility

Certain products are only available in select territories. Please contact your local Sales Representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Subtype:
Frozen
Cell Type:
Cardiac Cells
Species:
Human
Cell and Tissue Source:
Pluripotent Stem Cells

Technical Resources

Educational Materials

(3)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
Chat with an Expert